|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 9 (May 1), 2000:
pp. 2855-2859
Thrombin activatable fibrinolysis inhibitor and the
risk for deep vein thrombosis
Nico H. van Tilburg,
Frits R. Rosendaal, and
Rogier M. Bertina
From the Departments of Hematology and Clinical Epidemiology,
Hemostasis and Thrombosis Research Center, Leiden University Medical
Center, Leiden, The Netherlands.
Thrombin activatable fibrinolysis inhibitor (TAFI, or
procarboxypeptidase B) is the precursor of a recently described
carboxypeptidase that potently attenuates fibrinolysis. Therefore, we
hypothesized that elevated plasma TAFI levels induce a hypofibrinolytic
state associated with an increased risk for venous thrombosis. To
evaluate this hypothesis, we developed an electroimmunoassay for TAFI
antigen and used this assay to measure TAFI levels in the Leiden
Thrombophilia Study, a case-control study of venous thrombosis in 474 patients with a first deep vein thrombosis and 474 age- and sex-matched control subjects. In 474 healthy control subjects, an increase of TAFI
with age was observed in women but not in men. Oral contraceptive use
also increased the TAFI concentration. TAFI levels above the 90th
percentile of the controls (> 122 U/dL) increased the risk for
thrombosis nearly 2-fold compared with TAFI levels below the 90th
percentile (odds ratio, 1.7; 95% confidence interval, 1.1-2.5). Adjustment for various possible confounders did not materially affect
this estimate. These results indicate that elevated TAFI levels form a
mild risk factor for venous thrombosis. Such levels were found in 9%
of healthy controls and in 14% of patients with a first deep vein
thrombosis. Elevated TAFI levels did not enhance the thrombotic risk
associated with factor V Leiden but may interact with high factor VIII levels.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. E. Meltzer, C. J.M. Doggen, P. G. de Groot, J. C.M. Meijers, F. R. Rosendaal, and T. Lisman
Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men
Haematologica,
June 1, 2009;
94(6):
811 - 818.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. M. Lijfering, J.-L. P. Brouwer, N. J. G. M. Veeger, I. Bank, M. Coppens, S. Middeldorp, K. Hamulyak, M. H. Prins, H. R. Buller, and J. van der Meer
Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives
Blood,
May 21, 2009;
113(21):
5314 - 5322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Erem, M. Kocak, I. Nuhoglu, M. Yilmaz, and O. Ucuncu
Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism
Eur. J. Endocrinol.,
May 1, 2009;
160(5):
863 - 868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Boffa, D. Maret, J. D. Hamill, N. Bastajian, P. Crainich, N. S. Jenny, Z. Tang, E. M. Macy, R. P. Tracy, R. F. Franco, et al.
Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis
Blood,
January 1, 2008;
111(1):
183 - 189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Buffat, F. Boubred, F. Mondon, S. T. Chelbi, J.-M. Feuerstein, M. Lelievre-Pegorier, D. Vaiman, and U. Simeoni
Kidney Gene Expression Analysis in a Rat Model of Intrauterine Growth Restriction Reveals Massive Alterations of Coagulation Genes
Endocrinology,
November 1, 2007;
148(11):
5549 - 5557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Binette, F. B. Taylor Jr, G. Peer, and L. Bajzar
Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon
Blood,
November 1, 2007;
110(9):
3168 - 3175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Brighton, J. Janssen, and S. P. Butler
Aging of Acute Deep Vein Thrombosis Measured by Radiolabeled 99mTc-rt-PA
J. Nucl. Med.,
June 1, 2007;
48(6):
873 - 878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sucker, G. R. Hetzel, F. Farokhzad, F. Dahhan, M. Schmitz, C. Kurschat, B. Grabensee, B. Maruhn-Debowski, R. Zotz, and R. Scharf
Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study
Nephrol. Dial. Transplant.,
May 1, 2007;
22(5):
1347 - 1350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. Halfdanarson, M. R. Litzow, and J. A. Murray
Hematologic manifestations of celiac disease
Blood,
January 15, 2007;
109(2):
412 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. O. Mosnier and B. N. Bouma
Regulation of Fibrinolysis by Thrombin Activatable Fibrinolysis Inhibitor, an Unstable Carboxypeptidase B That Unites the Pathways of Coagulation and Fibrinolysis
Arterioscler Thromb Vasc Biol,
November 1, 2006;
26(11):
2445 - 2453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Frere, D.-A. Tregouet, P.-E. Morange, N. Saut, D. Kouassi, I. Juhan-Vague, L. Tiret, and M.-C. Alessi
Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study
Blood,
September 1, 2006;
108(5):
1562 - 1568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Ceresa, E. Brouwers, M. Peeters, C. Jern, P. J. Declerck, and A. Gils
Development of ELISAs Measuring the Extent of TAFI Activation
Arterioscler Thromb Vasc Biol,
February 1, 2006;
26(2):
423 - 428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Demirkan, M. A. Ozcan, A. Alacacioglu, F. Yuksel, B. Undar, and M. Alakavuklar
The Effect of Anthracycline-Based (Epirubicin) Adjuvant Chemotherapy on Plasma TAFI and PAI-1 Levels in Operable Breast Cancer
Clinical and Applied Thrombosis/Hemostasis,
January 1, 2006;
12(1):
9 - 14.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. L. Willemse and D. F. Hendriks
Measurement of Procarboxypeptidase U (TAFI) in Human Plasma: A Laboratory Challenge
Clin. Chem.,
January 1, 2006;
52(1):
30 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Renckens, J. J. T. H. Roelofs, S. A. J. ter Horst, C. van 't Veer, S. R. Havik, S. Florquin, G. T. M. Wagenaar, J. C. M. Meijers, and T. van der Poll
Absence of Thrombin-Activatable Fibrinolysis Inhibitor Protects against Sepsis-Induced Liver Injury in Mice
J. Immunol.,
November 15, 2005;
175(10):
6764 - 6771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Kaftan, O. S. Balcik, H. Cipil, G. Ozet, N. Bavbek, A. Kosar, and S. Dagdas
Plasma Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Primary and Secondary Thrombocytosis
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2005;
11(4):
449 - 454.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. Aso, S. Wakabayashi, R. Yamamoto, R. Matsutomo, K. Takebayashi, and T. Inukai
Metabolic Syndrome Accompanied by Hypercholesterolemia Is Strongly Associated With Proinflammatory State and Impairment of Fibrinolysis in Patients With Type 2 Diabetes: Synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor
Diabetes Care,
September 1, 2005;
28(9):
2211 - 2216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Arolas, J. Lorenzo, A. Rovira, J. Castella, F. X. Aviles, and C. P. Sommerhoff
A Carboxypeptidase Inhibitor from the Tick Rhipicephalus bursa: ISOLATION, cDNA CLONING, RECOMBINANT EXPRESSION, AND CHARACTERIZATION
J. Biol. Chem.,
February 4, 2005;
280(5):
3441 - 3448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Lisman, P. G. de Groot, J. C.M. Meijers, and F. R. Rosendaal
Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis
Blood,
February 1, 2005;
105(3):
1102 - 1105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Rosendaal
Venous Thrombosis: The Role of Genes, Environment, and Behavior
Hematology,
January 1, 2005;
2005(1):
1 - 12.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. Smith, S. R. Heckbert, R. N. Lemaitre, A. P. Reiner, T. Lumley, N. S. Weiss, E. B. Larson, F. R. Rosendaal, and B. M. Psaty
Esterified Estrogens and Conjugated Equine Estrogens and the Risk of Venous Thrombosis
JAMA,
October 6, 2004;
292(13):
1581 - 1587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Eichinger, V. Schonauer, A. Weltermann, E. Minar, C. Bialonczyk, M. Hirschl, B. Schneider, P. Quehenberger, and P. A. Kyrle
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
Blood,
May 15, 2004;
103(10):
3773 - 3776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Suzuki, Y. Muto, K. Fushihara, K.-i. Kanemoto, H. Iida, E. Sato, C. Kikuchi, T. Matsushima, E. Kato, M. Nomoto, et al.
J. Pharmacol. Exp. Ther.,
May 1, 2004;
309(2):
607 - 615.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Caprini, C. J. Glase, C. B. Anderson, and K. Hathaway
Laboratory Markers in the Diagnosis of Venous Thromboembolism
Circulation,
March 30, 2004;
109(12_suppl_1):
I-4 - I-8.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Colucci, B. M. Binetti, A. Tripodi, V. Chantarangkul, and N. Semeraro
Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism
Blood,
March 15, 2004;
103(6):
2157 - 2161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Voetsch and J. Loscalzo
Genetic Determinants of Arterial Thrombosis
Arterioscler Thromb Vasc Biol,
February 1, 2004;
24(2):
216 - 229.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Santamaria, A. Oliver, M. Borrell, J. Mateo, R. Belvis, J. Marti-Fabregas, R. Ortin;, I. Tirado, J.C. Souto, and J. Fontcuberta
Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma Levels
Stroke,
October 1, 2003;
34(10):
2387 - 2391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. O. Mosnier, P. Buijtenhuijs, P. F. Marx, J. C. M. Meijers, and B. N. Bouma
Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets
Blood,
June 15, 2003;
101(12):
4844 - 4846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gils, M.-C. Alessi, E. Brouwers, M. Peeters, P. Marx, J. Leurs, B. Bouma, D. Hendriks, I. Juhan-Vague, and P. J. Declerck
Development of a Genotype 325-Specific proCPU/TAFI ELISA
Arterioscler Thromb Vasc Biol,
June 1, 2003;
23(6):
1122 - 1127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Montaner, M. Ribo, J. Monasterio, C. A. Molina, and J. Alvarez-Sabin
Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic Stroke
Stroke,
April 1, 2003;
34(4):
1038 - 1040.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Crowther and J. G. Kelton
Congenital Thrombophilic States Associated with Venous Thrombosis: A Qualitative Overview and Proposed Classification System
Ann Intern Med,
January 21, 2003;
138(2):
128 - 134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Boffa, J. D. Hamill, N. Bastajian, R. Dillon, M. E. Nesheim, and M. L. Koschinsky
A Role for CCAAT/Enhancer-binding Protein in Hepatic Expression of Thrombin-activable Fibrinolysis Inhibitor
J. Biol. Chem.,
July 5, 2002;
277(28):
25329 - 25336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Juhan-Vague, P.E. Morange, H. Aubert, M. Henry, M.F. Aillaud, M.C. Alessi, A. Samnegard, E. Hawe, J. Yudkin, M. Margaglione, et al.
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe
Arterioscler Thromb Vasc Biol,
May 1, 2002;
22(5):
867 - 873.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. V. Kakkar, D. A. Hoppenstead, J. Fareed, Z. Kadziola, M. Scully, R. Nakov, and H. K. Breddin
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis
Blood,
March 15, 2002;
99(6):
1965 - 1970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Bauer, F. R. Rosendaal, and J. A. Heit
Hypercoagulability: Too Many Tests, Too Much Conflicting Data
Hematology,
January 1, 2002;
2002(1):
353 - 368.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G.-J. Brouwers, H. L. Vos, F. W. G. Leebeek, S. Bulk, M. Schneider, M. Boffa, M. Koschinsky, N. H. van Tilburg, M. E. Nesheim, R. M. Bertina, et al.
A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels
Blood,
September 15, 2001;
98(6):
1992 - 1993.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Bauer
The Thrombophilias: Well-Defined Risk Factors with Uncertain Therapeutic Implications
Ann Intern Med,
September 4, 2001;
135(5):
367 - 373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tripodi and P. M. Mannucci
Laboratory Investigation of Thrombophilia
Clin. Chem.,
September 1, 2001;
47(9):
1597 - 1606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Vandenbroucke, J. Rosing, K. W.M. Bloemenkamp, S. Middeldorp, F. M. Helmerhorst, B. N. Bouma, and F. R. Rosendaal
Oral Contraceptives and the Risk of Venous Thrombosis
N. Engl. J. Med.,
May 17, 2001;
344(20):
1527 - 1535.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Schatteman, F. Goossens, J. Leurs, R. Verkerk, S. Scharpe, J. J. Michiels, and D. Hendriks
arboxypeptidase U at the Interface Between Coagulation and Fibrinolysis
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2001;
7(2):
93 - 101.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Henry, H. Aubert, P. E. Morange, I. Nanni, M.-C. Alessi, L. Tiret, and I. Juhan-Vague
Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled
Blood,
April 1, 2001;
97(7):
2053 - 2058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bajzar
Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway
Arterioscler Thromb Vasc Biol,
December 1, 2000;
20(12):
2511 - 2518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
